

Global predictions of short- to medium-term COVID-19 transmission trends: a retrospective assessment

Sangeeta Bhatia^{1, *}, Kris V Parag¹, Jack Wardle¹, Natsuko Imai¹, Sabine L Van Elsland¹, Britta Lassmann², Gina Cuomo-Dannenburg¹, Elita Jauneikaite¹, H. Juliette T. Unwin¹, Steven Riley¹, Neil Ferguson¹, Christl A Donnelly^{1, 3}, Anne Cori¹, Pierre Nouvellet^{1, 4}

1 MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, UK.

2 ProMED, International Society for Infectious Diseases, Brookline, MA, USA.

3 Department of Statistics, University of Oxford, Oxford, UK.

4 School of Life Sciences, University of Sussex, Brighton, UK.

* s.bhatia@imperial.ac.uk

Abstract

Background As of July 2021, more than 180,000,000 cases of COVID-19 have been reported across the world, with more than 4 million deaths. Mathematical modelling and forecasting efforts have been widely used to inform policy-making and to create situational awareness.

Methods and Findings From 8th March to 29th November 2020, we produced weekly estimates of SARS-CoV-2 transmissibility and forecasts of deaths due to COVID-19 for countries with evidence of sustained transmission. The estimates and forecasts were based on an ensemble model comprising of three models that were calibrated using only the reported number of COVID-19 cases and deaths in each country. We also developed a novel heuristic to combine weekly estimates of transmissibility and potential changes in population immunity due to infection to produce forecasts over a 4-week horizon. We evaluated the robustness of the forecasts using relative error, coverage probability, and comparisons with null models.

Conclusions During the 39-week period covered by this study, we produced short- and medium-term forecasts for 81 countries. Both the short- and medium-term forecasts captured well the epidemic trajectory across different waves of COVID-19 infections with small relative errors over the forecast horizon. The model was well calibrated with 56.3% and 45.6% of the observations lying in the 50% Credible Interval in 1-week and 4-week ahead forecasts respectively. We could accurately characterise the overall phase of the epidemic up to 4-weeks ahead in 84.9% of country-days. The medium-term forecasts can be used in conjunction with the short-term forecasts of COVID-19 mortality as a useful planning tool as countries continue to relax stringent public health measures that were implemented to contain the pandemic.

Introduction

As of July 2021, more than 4 million deaths have been attributed to COVID-19 with over 180 million cases reported globally [1]. The scale of the current pandemic has led to a widespread adoption of data-driven public health responses across the globe. Epidemiological quantities such as the reproduction number and the herd immunity threshold have become a part of the public discourse, used by governments to plan their response and by the media to aid public understanding of the health emergency. Outbreak analysis and real-time modelling, including short-term forecasts of future incidence, have been used to inform decision making and response efforts in several past public health challenges including the West African Ebola epidemic and seasonal influenza [2–11]. In the current pandemic, mathematical models have helped public health officials better understand the evolving epidemiology of SARS-CoV-2 [12–14] and the potential impact of implementing or releasing interventions. Short-term forecasts of key indicators such as mortality, hospitalisation, and hospital occupancy have played a similarly important role [15–20], contributing to planning public health interventions and allocation of crucial resources [21–25]. At the same time, the unprecedented level of public interest has placed epidemiological modelling under intense media scrutiny. While model validation against observed data is part of a typical analysis pipeline, in light of the prominent role mathematical models have had in policy planning during the COVID-19 pandemic, retrospective assessment of modelling outputs against later

empirical data is critical to assess their validity. 58

With the aim of improving situational awareness during the ongoing pandemic, since 59
the 8th March 2020 we have been reporting weekly estimates of transmissibility of 60
SARS-CoV-2 and forecasts of the daily incidence of deaths associated with COVID-19 61
for countries with evidence of sustained transmission [26]. We have developed three 62
models that are calibrated using the latest reported incidence of COVID-19 cases and 63
deaths in each country that we combine into an ensemble model. 64

All models make implicit or explicit assumptions about the data-generating process 65
being modelled. In addition to the uncertainty associated with the model outputs, 66
there is inherent structural uncertainty about the models themselves as each model 67
makes different assumptions about transmission in attempting to approximate the true 68
underlying processes. Ensemble models, which combine outputs from different models, 69
are a powerful way of incorporating the uncertainty from a range of models [27,28]. They 70
are used widely in diverse fields such as weather forecasting, economics, ecology and are 71
increasingly being used in infectious disease forecasting. Ensemble models can produce 72
more robust forecasts than individual models [28–31]. The estimates of transmissibility 73
and short-term forecasts presented here are based on a novel ensemble model that was 74
calibrated across multiple waves of the pandemic. 75

Forecasts are typically produced under the assumption that the trend in growth 76
remain the same over the forecast horizon. This is a plausible assumption for the 1-week 77
forecast horizon that we used for our short-term forecasts. However, this assumption is 78
likely to be violated over a long forecast horizon for a rapidly evolving epidemic such as 79
COVID-19, leading to a rapidly increasing uncertainty as the forecast horizon grows. 80
We have developed a novel approach relying on a simple heuristic that combines past 81
estimates of the reproduction number, explicitly accounting for the predicted future 82
changes in population immunity, to produce forecasts over longer time horizons. 83

Here we summarise the key transmission trends from our work on global short-term 84
forecasts between 8th March to 29th November 2020. We provide a rigorous quantitative 85
assessment of the performance of the ensemble model. We also present medium-term 86
forecasts using our approach and retrospectively assess the performance of our method. 87
Our results for medium-term forecasts suggest that we can accurately forecast the 88
trajectory of COVID-19 in several countries for horizons spanning up to 4 weeks. 89

Materials and methods

Methods for estimating transmissibility during epidemics typically rely on the time series of incident cases combined with the natural history parameters of the pathogen [32, 33]. However, in the current pandemic, interpretation and comparison of estimates across countries based on the number of cases was made difficult by the differences in case definitions, testing regimes, and variable reporting across countries as well as over time within each country [34]. We therefore developed methods that relied on the number of reported deaths to estimate COVID-19 transmissibility and to produce short-term forecasts of deaths. Since we use deaths to estimate transmissibility, our estimates reflect the epidemiological situation with a delay corresponding to the delay from infection to death [35]. Despite this, our estimates and the short-term forecasts contributed and continue to contribute to situational awareness by providing near real-time insights into the dynamics of the pandemic. They also provide useful, albeit indirect, evidence into the effectiveness of various interventions such as lockdowns and the impact of reopening.

The instantaneous reproduction number is frequently used to quantify transmissibility. It is defined as the average number of secondary cases that an individual infected at time t would generate if conditions remained as they were at time t [36]. When applied to the incidence of deaths (rather than cases), the instantaneous reproduction number R_t^D represents the average number of secondary deaths “generated by” the death of a primary case at time t . We developed three different models, each of which estimated transmissibility in the recent past and produced forecasts of COVID-19 deaths. We then incorporated the outputs of these models to build an ensemble model. We produced short-term forecasts (i.e. 1-week ahead), for which changes in the population immunity level could be ignored. We also produced medium-term forecasts (up to 4-weeks ahead) accounting for the depletion of the susceptible population due to the increased levels of natural host immunity. The methods underlying the individual models are illustrated in Fig. 1.

Hereafter, D_t and C_t represent the number of reported COVID-19 deaths and cases at time t respectively. Since we only used reported deaths to estimate transmissibility, for ease of notation, we drop the superscript D from R_t^D and use R_t to denote the instantaneous reproduction number with respect to deaths at time t . $R[t_1, t_2]$ is the

reproduction number between times t_1 and t_2 . The most recent estimate of transmissibility is denoted as R_T^{curr} . We use ω to denote the serial interval distribution of deaths i.e. the interval between the deaths of an infectee and their infector, where both the infector and the infectee die. Estimated incidence of deaths at time t is denoted by \hat{D}_t . T refers to last time point in the existing incidence time series of cases or deaths.

Model 1 (RtI0)

The first model relies on a well-established method [37] that assumes the daily incidence of deaths is approximated with a Poisson process following the renewal equation [36]:

$$D_t \sim \text{Poisson} \left(R_t \sum_{s=1}^t D_{t-s} \omega_s \right) \quad (1)$$

A standard approach to inferring recent transmissibility from an incidence time series relies on the assumption that the effective reproduction number is constant over a window (i.e. the “calibration window”) back in time of size τ time units (for example days or weeks) [33]. Adopting a similar approach here, we estimated R_t using only the data in a fixed time-window (of τ days) prior to the most recent observation to calibrate the model. We estimated the average transmissibility $R[T - \tau + 1, T]$ over that time-window, but made no assumptions regarding the epidemiological situation or transmissibility prior to this calibration window (Fig. 1a). Instead, we jointly estimated (using Markov Chain Monte Carlo (MCMC)) combinations of $R[T - \tau + 1, T]$ and the incidence of deaths prior to the calibration window \hat{D}_t for $t = \{1, 2, \dots, T - \tau\}$ that are consistent with the observed deaths in the time window $[T - \tau + 1, T]$. The model likelihood is given by

$$\begin{aligned} \mathcal{L} \left(\langle \hat{D}_t \rangle, R[T - \tau + 1, T] \mid D_{T-\tau+1}, \dots, D_T \right) \\ = \prod_{s=T-\tau+1}^T P \left(D_s \mid \langle \hat{D}_t \rangle, R[T - \tau + 1, T], D_{T-\tau+1}, \dots, D_{s-1} \right) \\ = \prod_{s=T-\tau+1}^T \text{Poisson} \left(D_s \mid R[T - \tau + 1, T] \sum_{k=1}^s D_{s-k} \omega_k \right) \end{aligned} \quad (2)$$

where $\langle \hat{D}_t \rangle = \{D_1, D_2, \dots, D_{T-\tau}\}$ and $\hat{D}_t = D_t$ for $t = T - \tau + 1, \dots, T$. The

most recent estimate of transmissibility R_T^{curr} in this model is $R[T - \tau + 1, T]$. We then sampled sets of back-calculated early incidence time series $(\hat{D}_1, \dots, \hat{D}_{T-\tau})$ and reproduction numbers $(R[T - \tau + 1, T])$ from the joint posterior distribution obtained in the estimation process, and projected future incidence \hat{D}_{T+i} for $i \geq 1$ conditional on these as follows:

$$\hat{D}_{T+i} \sim \text{Poisson} \left(R_T^{curr} \sum_{k=1}^{T+i-1} D_{T+i-k} \omega_k \mid R_T^{curr}, \hat{D}_1, \dots, \hat{D}_{T-\tau}, D_{T-\tau+1}, \dots, D_T, \hat{D}_{T+1}, \dots, \hat{D}_{T+i-1} \right), \quad (3)$$

where $\hat{D}_t = D_t$ for $t = T - \tau + 1, \dots, T$. During the period covered in the analysis, the epidemiological situation in most countries was changing rapidly with public health measures being reviewed weekly. At the same time, there was a strong ‘weekend effect’ in the observed data, with typically fewer deaths reported on Saturdays and Sundays. We therefore assumed a fixed calibration window of 10 days to incorporate the rapid dynamics and offset the lower reporting over the weekend. We ran the MCMC for 10000 iterations. We sampled 1000 sets of R_T^{curr} and back-calculated incidence, and for each sampled set, we drew 10 stochastic realisations of the projected incidence of deaths.

Model 2 (APEestim)

Similarly to Model 1, Model 2 relies on the renewal equation (Eq. (1)) but uses the full time series of observed deaths, and uses information theory to optimise the choice of the calibration window i.e. the time-window of size τ over which $R[T - \tau + 1, T]$ is assumed to be constant in the estimation process [38]. Choices of window size can influence the bias and variance of resulting estimates of transmissibility [39]. We integrated over the entire posterior distribution of R_t (under a given window size), to obtain the posterior predictive distribution of incidence at time $t + 1$ as

$$P(D_{t+1} \mid D_1, D_2, \dots, D_t) = \int_{\mathcal{R}[t-\tau+1, t]} P(R_t) P(D_{t+1} \mid D_1, D_2, \dots, D_t, R_t) dR_t \quad (4)$$

where $\mathcal{R}[t - \tau + 1, t]$ represents the posterior distribution of R_t assuming a window of length τ . We computed this distribution sequentially for $t \in \{1, 2, \dots, T - 1\}$ and then evaluated every observed count of deaths according to their likelihood under the posterior predictive distribution. This allowed us to construct the accumulated predictive error (APE) for a window length τ and under a given serial interval distribution as [38]:

$$APE_\tau = \sum_{t=1}^{T-1} -\log P(D_{t+1} | D_1, D_2, \dots, D_t) \quad (5)$$

Here, D_{t+1} is the observed number of deaths at time $t+1$. The optimal window length τ^* was then chosen as the window for which APE_τ is minimised (Fig. 1b), optimising the bias-variance trade-off (long windows reduce the estimate variance but increase bias and short windows do the converse).

Again, forward projections were made assuming that transmissibility over the projection horizon remains the same as that in the last τ^* days. That is, R_T^{curr} is set to be $R[T - \tau^* + 1, T]$. We then obtain forecasts of deaths as

$$\hat{D}_{T+i} \sim \text{Poisson} \left(R_T^{curr} \sum_{k=1}^{T+i-1} D_{T+i-k} \omega_k | D_1, \dots, D_T, \hat{D}_{T+1}, \dots, \hat{D}_{T+i-1} \right), \quad (6)$$

for $i \geq 1$. We drew 1000 samples from the posterior distribution of R_T^{curr} and for each sampled value, simulated 10 forward trajectories.

Model 3 (DeCa)

Models 1 (RtI0) and 2 (APEestim) use only the time series of deaths to estimate R_t . Model 3 exploits the signal from both the reported deaths and cases to forecast deaths. We assumed that the delay δ between a case being reported and the case dying (for those who die) is distributed according to a gamma distribution with mean μ and standard deviation σ . Let f_Γ be the probability mass function of a discretised gamma distribution. The cumulative number of reported cases at time t weighted by the delay distribution from case report to death, $\sum_0^\infty f_\Gamma(x | \mu, \sigma) C_{t-x}$, represents the potential number of deaths at time t , if all cases were to die. The ratio ρ_t of the observed number of deaths to this

quantity at time t can be thought of as an observed case fatality ratio (Fig. 1c). We
 188
 assume that deaths are distributed according to a binomial distribution:
 189

$$D_t \sim \text{Binomial} \left(\sum_0^{\infty} f_{\Gamma}(x | \mu, \sigma) C_{t-x}, \rho_t \right). \quad (7)$$

The model likelihood is given by
 190

$$\begin{aligned} \mathcal{L}(\rho_1, \rho_2, \dots, \rho_T | C_1, \dots, C_T, D_1, D_2 \dots D_T, \mu, \sigma) \\ &= \prod_{s=1}^T P(D_s | C_1, \dots, C_s, \rho_s, \mu, \sigma) \\ &= \prod_{s=1}^T \text{Binomial} \left(\sum_0^{\infty} f_{\Gamma}(x | \mu, \sigma) C_{s-x}, \rho_s | C_1, \dots, C_s, \rho_s, \mu, \sigma \right). \end{aligned} \quad (8)$$

We obtained a posterior distribution for $\rho_1, \rho_2, \dots, \rho_T$ using the conjugate beta
 191
 prior for ρ_t (using the R package binom [40]), assuming that parameters of the delay
 192
 distribution μ and σ are known and fixed. The forecasted number of deaths at time
 193
 $T + i$ for $i \geq 1$ were then drawn from a binomial distribution as
 194

$$\hat{D}_{T+i} \sim \text{Binomial} \left(\sum_{k=0}^{T+i-1} f_{\Gamma}(k | \mu, \sigma) C_{T+i-k}, \rho_T \right). \quad (9)$$

Note that the number of deaths at time $T + i$ depends on the number of cases from
 195
 the beginning of the epidemic to time $T + i$ for $i \geq 1$. That is, for forecasting deaths
 196
 at time $T + i$, we need the number of cases at time $t > T$. To augment the observed
 197
 time series of cases, we assumed that the cases in beyond T are distributed according to
 198
 a gamma distribution with mean and standard deviation of the observed cases in the
 199
 last week, implicitly assuming no growth or decline in cases. We assessed the extent to
 200
 which this assumption affected our results (SI Sec. 4). Finally, to include transmissibility
 201
 estimates from this model in the ensemble, we estimated R_T^{curr} using the observed and
 202
 median forecasted deaths $D_1, \dots, D_T, \hat{D}_{T+i}$ for $i \geq 1$. using the R package EpiEstim [33].
 203

We drew 10000 samples from the posterior distribution of ρ_T and 10000 samples
 204
 from a gamma distribution to augment the observed cases. We then drew 10000 samples
 205

from a binomial distribution (Eq. (9)) for each pair of augmented cases trajectory and
sampled ρ_T .

Ensemble Model

We combined the estimates of R_T^{curr} , and the outputs of models RtI0, APEestim, and
DeCa into an unweighted ensemble model by sampling the forecasts and reproduction
number from each model described above. We also explored building a weighted ensemble
by weighting the contribution of each model according to the relative error of the model
in the previous week, all previous weeks, across all countries, or estimating the weights
independently for each country. We did not find any substantial difference in the
performance of the unweighted and weighted ensembles (not shown here). We therefore
restricted our analyses to an unweighted ensemble model.

We first drew 10000 samples from the posterior distribution of R_T^{curr} and forecasts
from each model and then sampled each posterior distribution with equal weight to build
the ensemble posterior distribution of R_T^{curr} and corresponding forecasts.

Short-term forecast horizon

The short-term forecast horizon was set to be 1 week. We produced forecasts for the
week ahead (Monday to Sunday) using the latest data up to (and including) Sunday.
We did not model the potential changes in the population immunity levels as any such
change is not expected to affect the trajectory of the epidemic over this short time
horizon.

Medium-term forecasts

Over the course of the epidemic, the effect of the potential depletion of the susceptible
population on the trajectory of the epidemic may become more pronounced. Inherently,
by estimating transmissibility in real-time, the models outlined above account for any
general decrease in the proportion of population being susceptible. However, the forecasts
produced do not account for any further decrease in this proportion, which may become
substantial when forecasting over a medium- to long-term time horizon.

Estimating transmissibility for medium-term forecasts

233

To better capture ongoing trends in transmissibility over time, we examined changes in
past ensemble estimates of R_T^{curr} in consecutive weeks. To forecast over a time horizon
longer than a week, we developed a novel heuristic that uses, in addition to the estimates
of R_T^{curr} , estimates from earlier weeks which are combined into a single weighted estimate
 R_T^w as follows. Starting with the estimates of R_T^{curr} , we went back one week at a time,
for as long as the 95% credible interval (CrI) of $R_{T'}^{curr}$ (where $T' < T$) overlapped the
95% CrI of R_T^{curr} . We then sampled from the posterior distribution of $R_{T'}^{curr}$ in each of
those weeks, with a probability that decays exponentially in the past to favour the more
recent estimates. That is, the distribution of R_{T-7k}^{curr} contributed to R_T^w with a relative
weight proportional to $e^{-\beta k}$ (Fig. 1d). Each week, the rate of decay β was optimised by
minimising the relative error in the predictions for the previous week.

234

235

236

237

238

239

240

241

242

243

244

Accounting for depletion of the susceptible population due to naturally-acquired immunity

245

246

As the weighted reproduction number R_t^w already accounts for the population immunity
at time t , we first estimated an effective reproduction number R_t^{eff} , defined as the
reproduction number if the entire population were susceptible. That is,

247

248

249

$$R_t^{eff} = \frac{R_t^w}{p_t^S} \quad (10)$$

where R_t^w is the weighted reproduction number at time t and p_t^S is the proportion of
population that is susceptible to infection at time t . p_t^S is given by $1 - \sum_{j=0}^t I_j/N$ where
 I_j is the number of infections at time j and N is the total population. In estimating
the potential future population immunity using this formulation, we only accounted
for naturally acquired immunity assuming that the immunity acquired after infection
persists. Since we were forecasting deaths (rather than infections), the true number
of infections was estimated using a country-specific age-distribution weighted Infection
Fatality Ratio (IFR) (SI Sec. 3).

250

251

252

253

254

255

256

257

We then incorporated the effect of a declining proportion of susceptible population
due to naturally acquired immunity as

258

259

$$R_{t+i}^S = R_t^{eff} p_{t+i}^S \quad (11)$$

From the ensemble estimates of R_T^{curr} , we first estimated R_T^S . The medium-term forecasts were then produced using the renewal equation (Eq. (1)) and the forecasts used to update the estimates of R_{T+i}^S for each $i \geq 1$ over the forecast horizon.

Medium-term forecast horizon

The medium-term forecasts were made over a 4-week horizon using R_t^S . Since estimates of the weighted reproduction number could only be obtained once we had sufficient weekly estimates to combine, medium-term forecasts were produced from 29th March to 29th November 2020.

Epidemic Phase

Following Abbott et al. [41], we defined the epidemic phase in a country at time t using the distribution of the reproduction number at t (R_t^{curr} for the short-term forecasts and R_t^S for the medium-term forecasts). At time t , we defined the epidemic phase in a country to be:

- ‘definitely growing’ if $R_t^{curr} < 1$ in less than 5% of the samples of the posterior distribution;
- ‘likely growing’ if $R_t^{curr} < 1$ in less than 20% of the samples of the posterior distribution;
- ‘definitely decreasing’ if $R_t^{curr} > 1$ in less than 5% of the samples of the posterior distribution;
- ‘likely decreasing’ if $R_t^{curr} > 1$ in less than 20% of the samples of the posterior distribution;
- ‘indeterminate’ otherwise.

Assessing model performance

The model forecasts were validated against observed deaths as these became available. To quantitatively assess the performance of the model for both short- and medium-term forecasts, we used the mean relative error (MRE) and the coverage probability i.e. the proportion of observations that are in a given credible interval of the distribution of forecasts (SI Sec. 5). Following Gu [42], we compared the absolute error of the model (the absolute difference between the forecasts and observations averaged across simulated trajectories) with the error of a model that used (i) the average of the last 10 observations as a forecast for the week ahead (no growth), and (ii) forecasted using a linear model fitted to the last 10 observations (linear growth).

Data and epidemiological parameters

We used the number of COVID-19 cases and deaths reported by the World Health Organisation (WHO) [1]. Any data anomalies were corrected using data published by the European Centre for Disease Prevention and Control [43], or other sources (SI Sec. 2). For the weekly analysis, we defined a country as having evidence of active transmission if at least 100 deaths had been reported, and at least ten deaths were observed in each of the past two weeks (SI Sec. 2). Countries with large variability in the reported deaths within each week over the analysis period were excluded from the final analysis for this work (SI Sec. 2 lists the full exclusion criterion). Results for 81 countries were included in the work presented here.

We assumed a gamma distributed serial interval with mean 6.48 days and standard deviation of 3.83 days following [44]. For simplicity, we assumed that the delay in reporting a death is the same as the delay from onset to a case being reported. We assumed that the delay in reporting of deaths follows a gamma distribution with mean of 10 days, and standard deviation of 2 days. These figures are roughly consistent with an onset-to-death delay of 15.9 days [45] and onset-to-diagnosis delay of 6.6–6.8 days [46]. The serial interval and delay distributions were discretised using R package EpiEstim [33]. We used a country-specific population-adjusted IFR estimated using the IFR reported in the REACT study (SI Sec. 3).

Results

311

Short-term forecasts and model performance

312

Beginning 8th March 2020, we produced weekly forecasts for every country with evidence of sustained transmission. As the pandemic rapidly spread across the world, the number of countries included in the weekly analysis grew from 3 in the first week (week beginning 8th March 2020), to 94 in the last week of analysis included in this study (week beginning 29th November 2020) (SI Fig. 1).

Overall, the ensemble model performed well in capturing the short-term trajectory of the epidemic in each country. Across all weeks of forecast and all countries, an average 58.7% (SD 32.4%) of the observations were in the 50% credible interval (CrI) and 89.4% (SD 21.7%) of the observations were in 95% CrI (for a breakdown by country and week of forecast see SI Sec. 5.5).

The MRE across all countries and all weeks was 0.4 (SD 0.4) (Fig. 3). That is, on average the model forecasts were 0.4 times lower or higher than the observed incidence. In most countries, the reporting of both cases and deaths through the week was variable, with fewer numbers reported on some days of the week (typically, Saturday and Sunday). The variability in reported deaths strongly influenced the model performance. The MRE scaled linearly with the coefficient of variation (ratio of the standard deviation to the mean) in the reported deaths for the week of forecasting. Thus, the error in forecasts was on average similar to the variability in the reported deaths (SI Fig. 6). The MRE of the model scaled inversely with the weekly incidence i.e. the error was relatively large when the incidence was low (SI Fig. 6), as estimates of reproduction number when the incidence is low are inherently more unstable [47].

The model performance was largely consistent across epidemic phases (growing, likely growing, decreasing, likely decreasing and indeterminate) with similar coverage probability and MRE (SI Table 1). The slightly larger proportion of observations in the 50% and 95% credible intervals for the ‘indeterminate’ phase and the larger MRE in this phase together suggest that the model was ‘under-confident’ with large credible intervals [48].

We compared the performance of the model with that of a null no-growth model. In most instances, the ensemble model outperformed the null model. In 80.9% of the weeks

in ‘definitely decreasing’ phase and 61.4% of weeks in ‘definitely growing’ phase, the absolute error of the model was smaller than the error made by the null model (Fig. 3, SI Sec. 5.2, SI Table 2). The null model performed better when the trajectory of the epidemic in a country was relatively stable exhibiting little to no change over the time frame of comparison. This is to be expected as the null model describes precisely this stable dynamic. Indeed, in 68.1% of the weeks in the ‘likely growing’ phase and 67.1% weeks classified as ‘indeterminate’ phase, the absolute error of the model was larger than the error made by the null model. However, the relative error of the model remained small even in countries and weeks where it did not perform as well as the null model. Similarly, our model performed better than a linear growth model across all phases, specifically in 96.4% of the weeks in ‘definitely decreasing’ phase and 70.3% weeks in ‘definitely growing’ phase (SI Sec. 5.3, SI Table 2).

Medium-term forecasts and model performance

The rapidly changing situation and the various interventions deployed to stem the growth of the pandemic make forecasting at any but the shortest of time horizons extremely challenging [49]. Despite these challenges, we find that our medium-term forecasts were able to robustly capture the epidemic trajectory (Fig. 4) in all countries included in the analysis (4).

Overall, the MRE remained small over a 4-week forecast horizon, with errors increasing over the projection horizon (SI Sec. 6.1). We therefore restricted the projection horizon to 4 weeks. The MRE across all countries in 1-week ahead forecasts was 0.4 (SD 0.3), increasing to 2.6 (SD 28.3) in 4-week ahead forecasts (Fig. 5, SI Fig. 10). The MRE for 1-week ahead forecasts was less than 1 (indicating that the magnitude of the error was smaller than the observation) in 91.1% of weeks for which we produced forecasts. The corresponding figure for 4-week ahead forecasts was 66.0% (SI Table 3).

The proportion of observations in the 50% CrI remained consistent across the forecast horizon and varied from 56.3% (SD 33.4%) in 1-week ahead forecasts to 45.6% (SD 40.9%) in 4-week ahead forecasts (SI Fig. 11, SI Fig. 12).

More importantly, using R_t^S estimates from Eq. (11), we accurately characterised the phase of the epidemic in each country. Across the 81 countries and 2210 weeks

(15470 days) for which we produced both short- and medium-term forecasts, the phase definition using the reproduction number estimates from medium-term forecasts (R_t^S) was consistent with that using the estimates from the short-term forecasts (R_t^{curr}) in 87.6% (13559/15470) of country-days (number of countries X number of days for which we produced forecasts. The phase definition using reproduction number estimates from medium-term forecasts was updated each day over the forecast horizon while the short-term forecasts assigned the same phase to all days of a week.) in 1-week ahead forecasts and in 84.9% (13138/15470) of country-days in 4-week ahead forecasts (Fig. 6). When the phase definitions using R_t^S and R_t^{curr} were different, the medium-term estimates most frequently misclassified them as a phase with greater uncertainty. For instance, in 253 weeks when the epidemic phase was identified as ‘definitely decreasing’ using weekly estimates and incorrectly characterised using medium-term estimates, it was misclassified as ‘likely decreasing’ in 100% (253/253 weeks) of country-days. Similarly, in the misclassified weeks, when the epidemic phase using weekly transmissibility estimates was ‘definitely growing’, the medium-term classification was ‘indeterminate’ in 43.7% (1175/2688) and ‘likely growing’ in 56.3% (1513/2688) of the country-days. This mischaracterisation is expected as the uncertainty in estimates of R_t^S grows over the forecast horizon. Crucially, none of the weeks where R_t^S misclassified the epidemic phase, the phase using R_t^{curr} indicated the opposite trend (growing classified as decreasing or vice versa). This finding shows that the medium-term transmissibility estimates can be used a reliable indicator of the overall direction of the epidemic trajectory.

Discussion

Models used to forecast COVID-19 cases and/or deaths vary in complexity in the data used for model calibration. More complex and/or granular models rely on multiple data streams including data on hospital admissions and occupancy, testing, serological surveys and data on patient clinical progression and outcomes [21]. Such complex location-specific models can provide crucial insights into the ongoing epidemic and inform targeted public health interventions by synthesising evidence from different data streams. However, scaling such analysis to include multiple geographies is challenging because of the variability in availability and reliability of local surveillance data. The

computational time needed to fit complex models make scaling them difficult and delays 402
the timely provision of risk estimates. 403

In addition to the variable availability of surveillance data across countries, the wide- 404
scale societal and behavioural changes brought about by the pandemic impose practical 405
constraints on utilising data that are available for multiple countries. For instance, widely 406
available data on the changes in mobility inferred from mobile phone usage released by 407
Google and Apple were informative of the changes in transmission in the early phase of 408
the COVID-19 pandemic and were used in several modelling studies [50,51]. Although 409
these data continue to be available, recent evidence suggests a decoupling of transmission 410
and mobility in most countries [35,52]. Models that relied on such additional data [51] 411
or assumptions about non-pharmaceutical interventions [53] could not fit the observed 412
trajectory well as the situation continued to change over the course of the epidemic. 413

Efforts to model and forecast COVID-19 transmission dynamics must therefore meet 414
the challenges of a long and ongoing pandemic spread over an unprecedented scale. 415
Modelling groups around the world have attempted to meet one or both challenges with 416
various analyses conducted at a sub-national scale [54], at a national scale for a specific 417
country [22,55–57], and for several countries across the globe [41,58,59]. In contrast to 418
models built for a region or country and calibrated using local data, models that aim to 419
provide a global overview must be sufficiently general to describe the epidemic trajectory 420
in a range of countries/regions using widely available data that are consistently available 421
over time. 422

We have produced short-term forecasts and estimates of transmissibility for 81 423
countries for more than 65 weeks at the time of writing implementing three simple 424
models that use only the time series of COVID-19 cases and deaths. We have thus 425
traded particularity for generality, to allow us to carry out analysis for a large number 426
of countries over a long period of time. As our methods make few assumptions and use 427
routine surveillance data, they can be easily used during any other future outbreaks. 428

Despite the challenges inherent in forecasting a fast-moving pandemic in the presence 429
of unprecedented public health interventions, our ensemble model was able to successfully 430
capture the short-term transmission dynamics across all countries included in the analysis 431
with small relative error in the weekly forecasts across different COVID-19 waves in 432
each country. The variable performance of our model in weeks and countries with fewer 433

deaths and/or large variability in reported deaths over weeks reflects this trade-off. 434
In the absence of more detailed data, we assumed that epidemiological parameters 435
such as the delay from onset of symptoms to death were the same across all countries 436
and throughout the period of analysis. These parameters are likely to vary over time 437
and between countries and using country-specific parameters could lead to moderate 438
improvements in the model fits and forecast performance. 439

Due to the variability in testing and reporting of cases across different countries and 440
over time within countries, using the reported number of cases to estimate transmissibility 441
and produce forecasts is difficult without using more complex models. For these reasons, 442
we primarily used deaths to estimate the reproduction number as we assumed that 443
reporting of COVID-19 deaths was more complete and consistent over time and across 444
different country surveillance systems. Although this assumption is unlikely to hold for 445
many countries [60–62], our methods are robust to a constant rate of under-reporting 446
over time as this would not alter the overall epidemic trends. A limitation of our work is 447
that our estimates reflect the epidemiological situation with a delay of approximately 19 448
days (the delay from an infection to a death [53]). Nevertheless, our short-term forecasts 449
and transmissibility estimates provide a valuable global overview and continuous insights 450
into the dynamic trajectory of the epidemic in different countries. They also provide 451
indirect evidence about the effectiveness of public health measures. Future research 452
could investigate integrating more data streams into the models. In addition to the 453
weekly reports that we publish, our work has also contributed to other international 454
forecasting efforts [22, 48, 55]. 455

We developed a simple heuristic to combine past estimates of transmissibility and a 456
decline in the proportion of susceptible population to produce medium-term forecasts. 457
We were able to achieve good model performance in forecasting up to 4 weeks ahead. 458
Consistent with findings from other modelling studies [22], we found that the model 459
error was unacceptably high beyond 4 weeks, suggesting that forecasting beyond this 460
horizon is difficult. Importantly, our characterisation of the epidemic phase using 461
weighted estimates of transmissibility were largely in agreement with that using short- 462
term transmissibility estimates. Thus, our method was successful at capturing the 463
broad trends in transmission up to 4 weeks ahead. The medium-term forecasts can 464
therefore serve as a useful planning tool as governments around the world plan further 465

implementation or relaxation of non-pharmaceutical interventions. 466

Our method incorporates the depletion of susceptible population and hence can in 467
principle be extended to account for increasing population immunity as vaccination is 468
rolled out across the world. However, inclusion of vaccine induced immunity depends 469
on the availability of reliable data on vaccination coverage. Further, even if such data 470
were available, teasing apart the impact of vaccination on transmission and mortality 471
could be non-trivial. In light of these issues, it might be challenging to extend our 472
approach to rigorously assess the effect of vaccination on epidemic trajectory on a global 473
scale. However, our latest estimates of transmissibility indirectly reflect the impact of 474
vaccination on transmission, allowing for the delay from vaccination to full immunity, 475
and from infection to death. As we continue to track COVID-19 transmissibility globally, 476
any temporal changes in transmissibility would implicitly account for the changes due to 477
differential vaccination coverage. 478

Mathematical modelling and forecasting efforts have supported data-driven decision 479
making throughout this public health crisis. Our work has aimed to improve global 480
situational awareness. Using relatively simple approaches, we were able to produce 481
robust forecasts for COVID-19 in 81 countries and provide crucial and actionable insights. 482
This effort is being continued [26] as the world continues to grapple with renewed waves 483
of COVID-19 cases. 484

Supporting information 485

S1 File. Additional results. The supplementary file contains additional results on 486
model performance. 487

S1 2. Web tool. An interactive web-tool available at <https://shiny.dide.imperial.ac.uk/covid19-forecasts-shiny/> 488
presents both short- and medium-term forecasts, 489
and reproduction number estimates for all countries included in the analysis. 490

Acknowledgements 491

The authors acknowledge funding from the MRC Centre for Global Infectious Disease 492
Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council 493

(MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. JW acknowledges research funding from the Wellcome Trust (grant 102169/Z/13/Z). SB acknowledges funding from the Wellcome Trust (219415). This study is partially funded by the National Institute for Health Research (NIHR) Health Protection Research Unit in Modelling and Health Economics, a partnership between Public Health England, Imperial College London and LSHTM (grant code NIHR200908); and acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. The views expressed are those of the author(s) and not necessarily those of the NIHR, Public Health England or the Department of Health and Social Care.

References

1. WHO Coronavirus Disease (COVID-19) Dashboard; 2021. <https://covid19.who.int>.
2. Lipsitch M, Finelli L, Heffernan RT, Leung GM, Redd; for the 2009 H1N1 Surveillance Group SC. Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1. *Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science*. 2011;9(2):89–115.
3. WHO Ebola Response Team. Ebola Virus Disease in West Africa – The First 9 Months of the Epidemic and Forward Projections. *New England Journal of Medicine*. 2014;371:1481–1495. doi:10.1056/NEJMoa1411100.
4. The Ebola Outbreak Epidemiology Team. Outbreak of Ebola virus disease in the Democratic Republic of the Congo, April & May, 2018: an epidemiological study. *The Lancet*. 2018;392:213–221. doi:10.1016/S0140-6736(18)31387-4.

5. Nsoesie E, Mararthe M, Brownstein J. Forecasting Peaks
of Seasonal Influenza Epidemics. *PLoS Currents*. 2013;5.
doi:10.1371/currents.outbreaks.bb1e879a23137022ea79a8c508b030bc.
6. Bogoch II, Brady OJ, Kraemer MU, German M, Creatore MI, Kulkarni MA,
et al. Anticipating the international spread of Zika virus from Brazil. *The Lancet*.
2016;387(10016):335–336.
7. WHO Ebola Response Team. West African Ebola Epidemic after One Year — Slow-
ing but Not Yet under Control. *New England Journal of Medicine*. 2015;372(6):584–
587. doi:10.1056/NEJMc1414992.
8. Meltzer MI, Atkins CY, Santibanez S, Knust B, Petersen BW, Ervin ED, et al.
Estimating the future number of cases in the Ebola epidemic—Liberia and Sierra
Leone, 2014–2015. 2014;.
9. Barry A, Ahuka-Mundeke S, Ali Ahmed Y, Allarangar Y, Anoko J, Archer BN,
et al. Outbreak of Ebola virus disease in the Democratic Republic of the Congo,
April–May, 2018: an epidemiological study. *The Lancet*. 2018;392(10143):213–221.
doi:10.1016/S0140-6736(18)31387-4.
10. Biggerstaff M, Johansson M, Alper D, Brooks LC, Chakraborty P, Farrow DC, et al.
Results from the second year of a collaborative effort to forecast influenza seasons
in the United States. *Epidemics*. 2018;24:26–33. doi:10.1016/j.epidem.2018.02.003.
11. for the Influenza Forecasting Contest Working Group, Biggerstaff M, Alper D,
Dredze M, Fox S, Fung ICH, et al. Results from the Centers for Disease Control and
Prevention’s predict the 2013–2014 Influenza Season Challenge. *BMC Infectious
Diseases*. 2016;16(1):357. doi:10.1186/s12879-016-1669-x.
12. Verity R, Okell L, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of
the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infectious
Diseases*. 2020;doi:10.1016/S1473-3099(20)30243-7.
13. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coro-
navirus (COVID-19) infections. *International Journal of Infectious Diseases*.
2020;doi:10.1016/j.ijid.2020.02.060.

14. Ali ST, Wang L, Lau EH, Xu XK, Du Z, Wu Y, et al. Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions. *Science*. 2020;369(6507):1106–1109. doi:10.1126/science.abc9004.
15. Massonnaud C, Roux J, Crépey P. COVID-19: Forecasting short term hospital needs in France. *medRxiv*. 2020; p. 2020.03.16.20036939. doi:10.1101/2020.03.16.20036939.
16. Ahmadi A, Fadaei Y, Shirani M, Rahmani F. Modeling and forecasting trend of COVID-19 epidemic in Iran until May 13, 2020. *Medical Journal of the Islamic Republic of Iran*. 2020;34:27. doi:10.34171/mjiri.34.27.
17. Ferstad JO, Gu A, Lee RY, Thapa I, Shin AY, Salomon JA, et al. A model to forecast regional demand for COVID-19 related hospital beds. *medRxiv*. 2020; p. 2020.03.26.20044842. doi:10.1101/2020.03.26.20044842.
18. Reno C, Lenzi J, Navarra A, Barelli E, Gori D, Lanza A, et al. Forecasting COVID-19-Associated Hospitalizations under Different Levels of Social Distancing in Lombardy and Emilia-Romagna, Northern Italy: Results from an Extended SEIR Compartmental Model. *Journal of Clinical Medicine*. 2020;9(5):1492. doi:10.3390/jcm9051492.
19. IHME COVID-19 health service utilization forecasting team and Murray, Christopher JL. Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months. *medRxiv*. 2020; p. 2020.03.27.20043752. doi:10.1101/2020.03.27.20043752.
20. Goic M, Bozanic-Leal MS, Badal M, Basso LJ. COVID-19: Short-term forecast of ICU beds in times of crisis. *PLOS One*. 2021;16(1):e0245272. doi:10.1371/journal.pone.0245272.
21. Knock ES, Whittles LK, Lees JA, Perez-Guzman PN, Verity R, FitzJohn RG, et al. Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England. *Science Translational Medicine*. 2021; p. eabg4262. doi:10.1126/scitranslmed.abg4262.

22. Ray EL, Wattanachit N, Niemi J, Kanji AH, House K, Cramer EY, et al. Ensemble Forecasts of Coronavirus Disease 2019 (COVID-19) in the U.S. medRxiv. 2020;doi:10.1101/2020.08.19.20177493. 578-580
23. Roosa K, Lee Y, Luo R, Kirpich A, Rothenberg R, Hyman J, et al. Real-time forecasts of the COVID-19 epidemic in China from February 5th to February 24th, 2020. *Infectious Disease Modelling*. 2020;5:256–263. doi:10.1016/j.idm.2020.02.002. 581-583
24. IHME COVID-19 Forecasting Team. Modeling COVID-19 scenarios for the United States. *Nature Medicine*. 2020;doi:10.1038/s41591-020-1132-9. 584-585
25. Chintalapudi N, Battineni G, Amenta F. COVID-19 disease outbreak forecasting of registered and recovered cases after sixty day lockdown in Italy: A data driven model approach. *Journal of Microbiology, Immunology and Infection*. 2020;doi:10.1016/j.jmii.2020.04.004. 586-589
26. Short-term forecasts of COVID-19 deaths in multiple countries; 2021. <https://mrc-ide.github.io/covid19-short-term-forecasts/>. 590-591
27. Dormann CF, Calabrese JM, Guillera-Aroita G, Matechou E, Bahn V, Barton K, et al. Model averaging in ecology: a review of Bayesian, information-theoretic, and tactical approaches for predictive inference. *Ecological Monographs*. 2018;88(4):485–504. doi:10.1002/ecm.1309. 592-595
28. Buckee CO, Johansson MA. Individual model forecasts can be misleading, but together they are useful. *European Journal of Epidemiology*. 2020;35(8):731–732. 596-597
29. Johansson MA, Apfeldorf KM, Dobson S, Devita J, Buczak AL, Baugher B, et al. An open challenge to advance probabilistic forecasting for dengue epidemics. *Proceedings of the National Academy of Sciences*. 2019;116(48):24268–24274. doi:10.1073/pnas.1909865116. 598-601
30. Reich NG, McGowan CJ, Yamana TK, Tushar A, Ray EL, Osthus D, et al. Accuracy of real-time multi-model ensemble forecasts for seasonal influenza in the US. *PLoS Computational Biology*. 2019;15(11):e1007486. doi:10.1371/journal.pcbi.1007486. 602-605

31. Viboud C, Sun K, Gaffey R, Ajelli M, Fumanelli L, Merler S, et al. The RAPIDD Ebola forecasting challenge: Synthesis and lessons learnt. *Epidemics*. 2018;22:13–21. doi:10.1016/j.epidem.2017.08.002.
32. Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. *American Journal of Epidemiology*. 2004;160(6):509–516.
33. Cori A, Ferguson NM, Fraser C, Cauchemez S. A new framework and software to estimate time-varying reproduction numbers during epidemics. *American Journal of Epidemiology*. 2013;178(9):1505–1512. doi:10.1093/aje/kwt133.
34. Pullano G, Di Domenico L, Sabbatini CE, Valdano E, Turbelin C, Debin M, et al. Underdetection of cases of COVID-19 in France threatens epidemic control. *Nature*. 2021;590(7844):134–139. doi:10.1038/s41586-020-03095-6.
35. Nouvellet P, Bhatia S, Cori A, Ainslie KEC, Baguelin M, Bhatt S, et al. Reduction in mobility and COVID-19 transmission. *Nature Communications*. 2021;12(1):1090. doi:10.1038/s41467-021-21358-2.
36. Fraser C. Estimating individual and household reproduction numbers in an emerging epidemic. *PloS One*. 2007;2(8). doi:10.1371/journal.pone.0000758.
37. Nouvellet P, Cori A, Garske T, Blake IM, Dorigatti I, Hinsley W, et al. A simple approach to measure transmissibility and forecast incidence. *Epidemics*. 2018;22:29–35. doi:10.1016/j.epidem.2017.02.012.
38. Parag KV, Donnelly CA. Using information theory to optimise epidemic models for real-time prediction and estimation. *PloS Computational Biology*. 2020;16(7):e1007990. doi:10.1371/journal.pcbi.1007990.
39. Parag KV, Donnelly CA. Adaptive Estimation for Epidemic Renewal and Phylogenetic Skyline Models. *Systematic Biology*. 2020;69(6):1163–1179. doi:10.1093/sysbio/syaa035.
40. Dorai-Raj S. binom: Binomial Confidence Intervals For Several Parameterizations; 2014. Available from: <https://CRAN.R-project.org/package=binom>.

41. Abbott S, Hellewell J, Thompson RN, Sherratt K, Gibbs HP, Bosse NI, et al. 634
Estimating the time-varying reproduction number of SARS-CoV-2 using national 635
and subnational case counts. Wellcome Open Research. 2020;5(112):112. 636
42. Gu Y. COVID-19 projections using machine learning.; 2021. [https://](https://covid19-projections.com) 637
covid19-projections.com. 638
43. Situation updates on COVID-19; 2021. [https://www.ecdc.europa.eu/en/](https://www.ecdc.europa.eu/en/covid-19/situation-updates) 639
[covid-19/situation-updates](https://www.ecdc.europa.eu/en/covid-19/situation-updates). 640
44. Ferguson N, Laydon D, Nedjati Gilani G, Imai N, Ainslie K, Baguelin M, et al. 641
Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 642
mortality and healthcare demand. 2020;doi:10.25561/77482. 643
45. Khalili M, Karamouzian M, Nasiri N, Javadi S, Mirzazadeh A, Sharifi H. Epi- 644
demiological characteristics of COVID-19: a systematic review and meta-analysis. 645
Epidemiology and Infection. 2020;148:e130. doi:10.1017/S0950268820001430. 646
46. Li M, Chen P, Yuan Q, Song B, Ma J. Transmission characteristics of the COVID- 647
19 outbreak in China: a study driven by data. Epidemiology; 2020. Available 648
from: <http://medrxiv.org/lookup/doi/10.1101/2020.02.26.20028431>. 649
47. Parag KV. Improved estimation of time-varying reproduction numbers at low 650
case incidence and between epidemic waves. Epidemiology; 2020. Available from: 651
<http://medrxiv.org/lookup/doi/10.1101/2020.09.14.20194589>. 652
48. European Covid-19 Forecast Hub: Weekly reports; 2021. [https://](https://covid19forecasthub.eu/reports) 653
covid19forecasthub.eu/reports. 654
49. Castro M, Ares S, Cuesta JA, Manrubia S. The turning point and end of an 655
expanding epidemic cannot be precisely forecast. Proceedings of the National 656
Academy of Sciences. 2020;117(42):26190–26196. doi:10.1073/pnas.2007868117. 657
50. Vollmer MAC, Mishra S, Unwin HJT, Gandy A, Mellan TA, Bradley V, et al. A 658
sub-national analysis of the rate of transmission of COVID-19 in Italy. Public 659
and Global Health; 2020. Available from: [http://medrxiv.org/lookup/doi/10.](http://medrxiv.org/lookup/doi/10.1101/2020.05.05.20089359) 660
[1101/2020.05.05.20089359](http://medrxiv.org/lookup/doi/10.1101/2020.05.05.20089359). 661

51. Unwin HJT, Mishra S, Bradley VC, Gandy A, Mellan TA, Coupland H, et al. 662
State-level tracking of COVID-19 in the United States. *Nature Communications*. 663
2020;11(1):1–9. 664
52. Ainslie KEC, Walters CE, Fu H, Bhatia S, Wang H, Xi X, et al. Evidence of initial 665
success for China exiting COVID-19 social distancing policy after achieving contain- 666
ment. *Wellcome Open Research*. 2020;5:81. doi:10.12688/wellcomeopenres.15843.2. 667
53. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. 668
Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. 669
Nature. 2020;584(7820):257–261. doi:10.1038/s41586-020-2405-7. 670
54. Mishra S, Scott J, Zhu H, Ferguson NM, Bhatt S, Flaxman S, et al. A COVID-19 671
Model for Local Authorities of the United Kingdom. *medRxiv*. 2020;. 672
55. Bracher J, Wolfram D, Deuschel J, Goergen K, Ketterer JL, Ullrich A, et al. 673
Short-term forecasting of COVID-19 in Germany and Poland during the second 674
wave—a preregistered study. *medRxiv*. 2020;doi:10.1101/2020.12.24.20248826. 675
56. COVID-19 Austria; 2021. <https://www.covid19model.at>. 676
57. Hawryluk I, Mellan TA, Hoeltgebaum H, Mishra S, Schnekenberg RP, Whittaker 677
C, et al. Inference of COVID-19 epidemiological distributions from Brazilian 678
hospital data. *Journal of the Royal Society Interface*. 2020;17(172):20200596. 679
58. COVID-19 LMIC Reports; 2020. [https://mrc-ide.github.io/](https://mrc-ide.github.io/global-lmic-reports/) 680
[global-lmic-reports/](https://mrc-ide.github.io/global-lmic-reports/). 681
59. COVID-19 Daily Epidemic Forecasting; 2021. [https://renkulab.shinyapps.](https://renkulab.shinyapps.io/COVID-19-Epidemic-Forecasting) 682
[io/COVID-19-Epidemic-Forecasting](https://renkulab.shinyapps.io/COVID-19-Epidemic-Forecasting). 683
60. Alves THE, de Souza TA, de Almeida Silva S, Ramos NA, de Oliveira SV. 684
Underreporting of death by COVID-19 in Brazil’s second most populous state. 685
Frontiers in Public Health. 2020;8. 686
61. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 infections, 687
symptomatic infections, hospitalizations, and deaths using seroprevalence surveys. 688
JAMA Network Open. 2021;4(1):e2033706–e2033706. 689

62. Mwananyanda L, Gill CJ, MacLeod W, Kwenda G, Pieciak R, Mupila Z, et al. 690
Covid-19 deaths in Africa: prospective systematic postmortem surveillance study. 691
British Medical Journal. 2021;372. 692

Figures

693




Fig 1. Schematic of the models (a) Model 1 assumes a single value for $R[T - \tau + 1, T]$. The model is fitted using only the data in this window ($T - \tau + 1$ to T) to jointly estimate the initial incidence of deaths and $R[T - \tau + 1, T]$. (b) Model 2 optimises the window over which R_t is assumed to be constant by minimising the cumulative predictive error over the entire epidemic time series. Estimates from $R[T - \tau^* + 1, T]$ are used to forecast into the future, with τ^* the window of optimal length. (c) Model 3 uses data from both cases and deaths. The dashed blue curve represents the incidence of reported cases weighted by the case-report to death delay distribution, where μ is the mean delay. ρ_t is the ratio of the observed deaths and the weighted cases at time t and is analogous to an observed case fatality ratio. Forecasts of deaths are obtained by sampling from a binomial distribution using the most recent estimate of ρ_T . See also SI Fig. 3. (d) To obtain medium-term forecasts, we combine the most recent transmissibility estimate R_T^{curr} (shown in dark blue) with estimates of transmissibility in the previous weeks to produce a weighted estimate of transmissibility R_T^w (filled in pink) at time T . Estimates from previous weeks are combined with the most recent estimates if the 95% CrI of estimates in week k , R_{T-7k}^{curr} overlaps the 95% CrI of R_T^{curr} . Estimates for weeks where the 95% CrI overlap are shown in light purple, and where the 95% CrI do not overlap in grey. The dashed horizontal lines represent the 2.5th and 97.5th quantile of R_T^{curr} . We combine the estimates by sampling from the posterior distribution of R_{T-7k}^{curr} with probability proportional to $e^{-\beta*k}$, where β is a rate at which the probability decays as we go back in time.




Fig 2. Short-term forecasts. The short-term forecasts and observed deaths for six countries: Brazil, India, Italy, South Africa, Turkey and the United States of America (USA). For each country, the top panel shows the observed deaths in gray; the solid green line shows the median forecast. The shaded interval represents the 95% CrI of forecasts. The forecasts were produced using the most recent estimates of R_T^{curr} assuming that the transmissibility remains constant. The bottom panel for each country shows the effective reproduction number (R_T^{curr}) used to produce the forecasts. The solid green line in the bottom panel for each country is the median estimate of R_T^{curr} while the shaded region represents the 95% CrI. The dashed red line indicates the $R_T^{curr} = 1$ threshold. Note that the y-axis is different for each subfigure. See SI 2 for results for all other countries.




Fig 3. Short-term forecasts MRE and comparison with null model (a) The mean relative error of the ensemble model for each week of forecast (x-axis) and for each country (y-axis). Dark blue cells indicate weeks where the relative error of the model was greater than 2. (b) The ratio of the absolute error of the model to the absolute error of a no-growth null model that uses the average of the last 10 days as a forecast for the week ahead. Shades of green show weeks for a given country where the ratio was smaller than 1 i.e., the ensemble model error was smaller, and weeks where the ratio was greater than 1 i.e. the ensemble model error was larger than the null model error are shown in shades of red (yellow to red). Dark blue indicates weeks when the ratio was larger than 2. In order to present a representative sample, we first ranked all countries by the percentage of weeks in which ensemble model error was smaller than the null model error. We then selected every third country from the top 75 countries in this list. Results for the selected 25 countries are shown here. See SI Fig. 4 for the results for other countries. Ordering of countries in the figure reflects the order in the ranked list i.e. countries with the highest percentage of weeks with model error smaller than null model error are shown on the top.




Fig 4. Medium-term forecasts. The medium-term forecasts and observed deaths for six countries: Brazil, India, Italy, South Africa, Turkey and the United States of America (USA). For each country, the top panel shows the observed deaths in grey; the solid green line shows the median the 4-weeks ahead forecast. The shaded interval represents the 95% CrI of forecasts. The bottom panel for each country shows the median (solid black line) and the 95% CrI (grey shaded area) of weekly estimate of R_t^{curr} from the short-term forecasts and the median (green line) and the 95% CrI (shaded green area) of R_t^S i.e. the reproduction number accounting for depletion of susceptible population from the medium-term forecasts over a 4-week horizon (Methods). The dashed red line indicates the $R_t^S = 1$ threshold. Note that the y-axis is different for each subfigure. The forecasts were produced every week over a 4-week forecast horizon. The figure shows all non-overlapping forecasts over the course of the pandemic. See SI 2 for results for all other countries and weeks.




Fig 5. Relative error of medium-term forecasts. The mean relative error of the model in 1-week, 2-week, 3-week and 4-week ahead forecasts for each week when a forecast was made (x-axis) and for each country (y-axis). Blue cells indicate weeks where the relative error of the model was greater than 2. For ease of presentation, results are shown for the same 25 countries as Fig. 2. See SI Sec. 5 for the results for other countries.




Fig 6. Characterisation of the epidemic phase. For a given classification of epidemic phase using the weekly estimates of the reproduction number from the short-term forecasts(x-axis), the figures in the cell show the percentage of days for which the characterisation was consistent using the medium-term reproduction number estimates (shown on the y-axis)